All Articles

Here, we present the long-term follow-up data at up to 40 months.

Primary Analysis of Phase 2 Results for Cemiplimab in Patients with mBCC Who Progressed on or Were Intolerant to Hedgehog Inhibitors

AONN+ Conference Abstracts

November 2022 Vol 13, No 11

Here, we present the primary analysis of the mBCC cohort.

Category IX: Clinical Research

Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) (MOMENTUM)

AONN+ Conference Abstracts

November 2022 Vol 13, No 11

MMB, an oral JAK1/2 and ACVR1/ALK2 inhibitor, was evaluated (vs DAN) in a pivotal phase 3 study of MF patients previously treated with a JAK inhibitor (JAKi). This subgroup analysis evaluated MOMENTUM patients with baseline platelet counts ≤150 × 10⁹/L.

Category IX: Clinical Research

Upper Gastrointestinal (GI) Morbidity and Gastric Acid–Reducing Agent (GARA) Use Among Oncolytic-Treated Patients with Non-Hodgkin Lymphomas: Nursing Perspective Insights

Clinical Research, AONN+ Conference Abstracts

November 2022 Vol 13, No 11

To evaluate the epidemiology of upper GI morbidity, peptic ulcer risk, and prescription GARA use among patients with MCL or CLL/SLL and provide the nursing perspective on GARA use in oncology patient care.

Navigating Oral Therapy in Breast Cancer: Practice Strategies to Promote Medication Adherence

By Robert J. Ferguson, PhD; Madelaine C. Kuiper, NP; Maryam Lustberg, MD, MPH

Breast Cancer

Video Library

The Academy of Oncology Nurse & Patient Navigators (AONN+) and Eli Lilly and Company Medical Affairs are pleased to present a live webinar designed to facilitate conversations with patients regarding adherence to breast cancer treatments. Attendees will have an opportunity to participate in a live Q&A following the presentation.

LBA Category II: Care Coordination/Care Transitions

Coordination of Care/Care Transitions

October 2022 Vol 13, No 10

While it is generally recognized that oncology navigation programs can vary in structure, makeup, and domain of care, a common task expected of all navigators is identifying potential or existing barriers to cancer care.

LBA Category III: Patient Advocacy/Patient Empowerment

Patient Advocacy/Empowerment

October 2022 Vol 13, No 10

LBA Category VI: Research, Quality, Performance Improvement

Research/Quality/Performance Improvement

October 2022 Vol 13, No 10

LBA Category VII: Operations Management, Organizational Development, Health Economics

Operations Management, Organizational Development, Healthcare Economics

October 2022 Vol 13, No 10

LBA Category VIII: Survivorship and End of Life

Survivorship, End-of-Life

October 2022 Vol 13, No 10